

## Lumito attends the Digital Pathology & Al Congress in London

On December 7–8, Lumito will exhibit with a booth at the annual Digital Pathology & Al Congress in London. The presence is part of the company's branding work within the company's primary target group ahead of the upcoming launch of SCIZYS.

- It is important for us to build trust around our brand and product. We work to make ourselves visible early in the customer's buying journey to position our place in the minds of our primary target group. We exhibited at the Digital Pathology & Al Congress for the first time last year and see great value in returning this year to continue building on these relationships, comments CEO Mattias Lundin, who will attend with three colleagues in Sales & Marketing.

Lumito's SCIZYS product consists of a scanner and UCNP reagents (Upconverting Nano Particles staining liquids). According to the latest updated schedule, the assessment is to be completed, and CE mark SCIZYS in the first months of 2024.

## For further information, please contact:

Mattias Lundin, CEO Lumito

E-mail: ml@lumito.se Ph: +46 76 868 45 09

## Lumito

Lumito specialises in medical technology for digital pathology. Through its proprietary and patented technology, Lumito aims to provide healthcare providers with a powerful tool to meet the demands for fast and safe tissue diagnostics in personalised healthcare. The technology enables higher-contrast images without irrelevant background information, making it easier for pathologists to find cancer indications. The technology, based on Up Converting NanoParticles (UCNP), has the potential to significantly improve the diagnosis of tissue samples through higher quality analyses and shortened analysis times. The method has several potential applications, but Lumito has focused primarily on digital pathology and first on a release of SCIZYS by Lumito for use in research laboratories. The company is a spin-off of a research group at the Department of Atomic Physics and Laser Centre. www.lumito.se/en

The share is traded on NGM Nordic SME under the name LUMITO, and Mentor is Mangold Fondkommission.

## **Attachments**

Lumito attends the Digital Pathology & Al Congress in London